Our Research and Development Facilities
Bristol Myers Squibb's drug discovery and development work takes place across a network of state-of the-art facilities worldwide. For information about a specific Bristol Myers Squibb facility, click the link from the list below or view the complete list of our worldwide facilities.
The Biocon Bristol Myers Squibb Research & Development Center (BBRC) is a collaboration between Bristol Myers Squibb and Syngene International, a Biocon- group company, and is based in Bangalore, India. Fully operational since 2009, the site is involved in Target Identification, Lead Discovery and Lead Optimization all the way through to early stage Pharmaceutical Development and Clinical Biomarkers R&D.
Bristol Myers Squibb's European Research & Development operations have been based here since 2003. Employees work in eight buildings located in an office park set in the countryside.
In Cambridge, the company’s R&D site at Kendall Square focuses on understanding the complexities of cancer resistance, with cross-functional scientific teams collaborating throughout the drug discovery and translational medicine continuum. An R&D site in nearby Alewife similarly focuses on discovery biology, translational science, and chemistry research as well as other important functions for a number of other diseases including various immune-mediated and fibrotic conditions.
Purchased in 1905 when E.R. Squibb & Sons relocated operations from Brooklyn, New York, this campus has 40 buildings that total 1.9 million square feet on 96 acres. The site has evolved from a manufacturing site to become Bristol Myers Squibb's center for excellence for our therapeutic compounds.
The 276-acre campus serves as Bristol Myers Squibb's Research and Development headquarters. Here scientists discover and develop medicines in the areas of cancer, immunology, and cardiovascular diseases. The campus has 13 connected buildings totaling 1.5 million square feet.
Bristol Myers Squibb's European and French headquarters located 45 minutes from downtown Paris. The building, opened in August 2002, was designed by internationally recognized architect Jean-Paul Viguier.
Bristol Myers Squibb’s R&D campus in Redwood City, California focuses on the complexities of the tumor microenvironment. Here, teams examine various aspects of the microenvironment, collaborating closely with discovery and translational scientists across the country to research how we can harness the body’s own immune system to better target tumors.
Bristol Myers Squibb’s San Diego R&D site, located in the heart of the local life sciences ecosystem just a few miles away from picturesque La Jolla, houses several unique and industry-leading capabilities. The site focuses on the exploration of novel biology and target concepts – such as protein degradation – and complex biologics, aiming to better understand and modulate the biological processes that lead to cancer, multiple sclerosis and other diseases with significant unmet needs.
Bristol Myers Squibb’s San Francisco R&D site, located in the Mission Bay neighborhood, houses part of Bristol Myers Squibb’s early clinical development, medical and clinical scientist teams focused on hematology, oncology and cell therapy early phase trials. Physicians and clinical scientists here lead early clinical development programs for a diverse range of treatment modalities such as CAR T cells, T-cell engagers, monoclonal antibodies and small molecules. In addition, this site is home to translational scientists working in protein degradation and mechanisms of cancer resistance, and is connected with several Thematic Research Centers, predictive sciences and biosample operations.
Bristol Myers Squibb’s R&D site in the South Lake Union neighborhood of Seattle, Washington is at the center of the Company’s discovery, pipeline development and translational research efforts focused on cell therapy and immuno-oncology. Within this Thematic Research Center, scientists examine immune effector cell-based therapies such as CAR T cells, T-cell engagers, monoclonal antibodies and small molecules in both blood cancers and solid tumors. In addition, researchers in Seattle conduct extensive exploratory translational studies to support clinical studies and inform asset development strategies.
The BMS R&D site in Seattle is part of BMS’s larger Seattle-area presence, which also includes employees working to develop, manufacture and commercialize cell therapies at a BMS cell therapy manufacturing plant in nearby Bothell, WA.
Bristol Myers Squibb's Center for Innovation and Translational Research Europe (CITRE) R&D site in Seville, Spain is a capability center that brings together teams from our global Informatics and Predictive Sciences, early clinical development and Thematic Research Center organizations to contribute to Bristol Myers Squibb research efforts worldwide.
The site houses computational, clinical and biology research teams as well as dedicated computational research infrastructure and laboratory facilities. Alongside onsite research, the center serves to expand our innovation, collaboration and talent development footprint in Europe.
Bristol Myers Squibb’s R&D site in Summit, New Jersey focuses on nonclinical research and development, clinical pharmacology and early development and translational medicine for immunology, cardiovascular and fibrosis and hematology. Additionally, the Early Development Program Leadership organization, based here and in Princeton, New Jersey, collaborates across the organization in leading the development and implementation of compelling asset strategies across the portfolio.